KaydedilenlerDerginizi ekleyin

Dergiler / İstanbul Kuzey Klinikleri / 2021 / Cilt: 8 - Sayı: 2

ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol

Kemal MEMİSOGLU
Habip YILMAZ
Abdullah Emre GÜNER
Aral SÜRMELİ
Kemal KURAL
Erdoğan KOCAYİĞİT
Esra SAHİN
Perihan ALKAN
Cemal KAZEZOĞLU
Serdal ZELYURT
Isil MARAL
Sayfa
119–123
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

These differences were both statistically significant.CONCLUSION: The addition of favipiravir to the national COVID-19 treatment protocol may explain this rapid decrease in the rate of ICU admissions and intubation.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVE: The objective of this study was to understand the observational relationship between adoption of favipiravir into the national COVID-19 treatment protocol and intensive care unit (ICU) admission rates in Istanbul due to COVID-19.METHODS: Data were harvested from the “Public Health Management System-HSYS,” which collate centrally the records of all known cases of COVID-19.
📊
Temel Bulgular & Veri:The total number of cases, numbers admitted to ICU, and number undergoing intubation were compared between 2 time periods: 11th of March, the date on which the first case in Turkey was confirmed, to 30th of March; and March 30, to 10th of April, 5 days after Favipiravir was introduced into the treatment algorithm when, the records were examined.RESULTS: The percentage of patients requiring ICU admission diminished from 24% to 12%, whilst the percentage intubated fell from 77% to 66%.
💡
Sonuç & Katkı:These differences were both statistically significant.CONCLUSION: The addition of favipiravir to the national COVID-19 treatment protocol may explain this rapid decrease in the rate of ICU admissions and intubation.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

OBJECTIVE: The objective of this study was to understand the observational relationship between adoption of favipiravir into the national COVID-19 treatment protocol and intensive care unit (ICU) admission rates in Istanbul due to COVID-19.METHODS: Data were harvested from the “Public Health Management System-HSYS,” which collate centrally the records of all known cases of COVID-19. The total number of cases, numbers admitted to ICU, and number undergoing intubation were compared between 2 time periods: 11th of March, the date on which the first case in Turkey was confirmed, to 30th of March; and March 30, to 10th of April, 5 days after Favipiravir was introduced into the treatment algorithm when, the records were examined.RESULTS: The percentage of patients requiring ICU admission diminished from 24% to 12%, whilst the percentage intubated fell from 77% to 66%. These differences were both statistically significant.CONCLUSION: The addition of favipiravir to the national COVID-19 treatment protocol may explain this rapid decrease in the rate of ICU admissions and intubation.

🔖

Bu Makaleye Atıf Yap

MEMİSOGLU, K., YILMAZ, H., GÜNER, A. E., SÜRMELİ, A., KURAL, K., KOCAYİĞİT, E., SAHİN, E., ALKAN, P., KAZEZOĞLU, C., ZELYURT, S., MARAL, I. (2022). ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol. İstanbul Kuzey Klinikleri, Cilt: 8 - Sayı: 2, 119–123. https://ajindex.com/articles/551246

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20
  2. Coronavirus Update (Live): 6,513,890 cases and 384,642 deaths from COVID-19 virus pandemic - Worldometer (Internet). Available at: https://www.worldometers.info/coronavirus/. Accessed Jun 3, 2020
  3. COVID-19 - Yeni koronavirüs hastalığı (new coronavirus disease) (Internet). Available at: https://covid19bilgi.saglik.gov.tr/tr. Accessed Jun 2, 2020
  4. Pandemik influenza ulusal hazırlık planı (National pandemic influenza preparedness plan). Ankara: Ministry of Health of Turkey, Public Health Directorate; 2019. Available at: https://hsgm.saglik.gov.tr/tr/ bulasicihastaliklar-haberler/ulusal-pandemi-hazirlik-plani.html. Accessed May 25, 2020
  5. Algoritmalar C. COVID-19 Algoritmalar (COVID-19 Treatment Protocol- Version 1). Available at: https://covid19bilgi.saglik.gov.tr/ tr/algoritmalar. Accessed Jan 30, 2020
  6. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 2017;93:449–63
  7. Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc 2020;83:534–6
  8. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14:58–60
  9. Algoritmalar C. COVID-19 Algoritmalar (COVID-19 Treatment Protocol- Version 6). Available at: https://covid19bilgi.saglik.gov.tr/ tr/algoritmalar. Accessed Mar 25, 2020
  10. World Health Organization. Surveillance, rapid response teams, and case investigation. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/surveillance-andcase-definitions. Accessed May 18, 2020
  11. Microsoft Corporation. Microsoft Excel (Internet). 2018. Available at: https://office.microsoft.com/excel. Accessed Feb 24, 2021
  12. IBM Corp. IBM SPSS Statistics for Windows (Internet). Armonk, NY: IBM Corp; 2017. Available at: https://hadoop.apache.org. Accessed Feb 24, 2021
  13. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020;6:1192–8
  14. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infe